Trading Signals: ABBV Stock Price Prediction and Forecast (Mon. Mar. 17, 2014 - Fri. Dec. 22, 2023)(AbbVie Inc.)
| ABBV latest price $71.0997 (1.87%) ($69.7968 - $71.1942) on Thu. Aug. 31, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 0.88% (three month average) | RSI | 80 | Latest Price | $71.0997(1.87%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ABBV advances 0.9% a day on average for past five trading days. | Weekly Trend | ABBV advances 2.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ABBV advance at 0% a week (0% probability) XLV(61%) VYM(49%) IVE(47%) IWD(47%) SPLV(47%) | Factors Impacting ABBV price | ABBV will decline at least -0.44% in a week (0% probabilities). VIXM(-17%) TLT(-13%) UUP(-11%) IGOV(-4%) DIA(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -0.44% (StdDev 0.88%) | Hourly BBV | 0 () | Intraday Trend | 1.6% | | | |
|
5 Day Moving Average | $69.67(2.05%) | 10 Day Moving Average | $68.54(3.73%) | 20 Day Moving Average | $67.72(4.99%) | To recent high | 0% | To recent low | 15.1% | Market Cap | $125.44b | | | | AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. |